2024-09-11 - Analysis Report
## REGN Stock Analysis Report

**Company Overview:** Regeneron Pharmaceuticals, Inc. (REGN) is a biotechnology company that develops and commercializes life-changing medicines for serious diseases.

**Performance Analysis:**

**1. Performance vs. S&P 500 (VOO):**
- REGN's cumulative return is 150.02%, compared to 83.37% for the S&P 500. 
- REGN has outperformed the S&P 500 by 66.65% (93.02% relative to the historical range).

**2. Recent Price Movements:**
- Closing price: 1144.77
- 5-day moving average: 1155.0
- 20-day moving average: 1174.56
- 60-day moving average: 1102.37

**3. Technical Indicators:**
- RSI: 31.92, indicating the stock is potentially oversold.
- PPO: -0.87, suggesting a possible downward trend.
- Delta_Previous_Relative_Divergence: -6.98, indicating a short-term downtrend in relative performance.
- Expected Return: 5.23%, representing the potential maximum return over 5 years for a current investment.

**4. Recent Earnings and Outlook:**

| Date       | EPS     | Revenue     |
|-------------|---------|-------------|
| 2024-08-01 | 13.25   | 3.55 B$     |
| 2024-05-02 | 6.7     | 3.15 B$     |
| 2023-11-02 | 9.48    | 3.36 B$     |
| 2023-08-03 | 9.05    | 3.16 B$     |
| 2024-08-01 | 9.05    | 3.16 B$     |

The latest earnings report for 2024-08-01 showed EPS of 13.25, exceeding analysts' expectations. This strong performance indicates positive growth for REGN. 

**5. Overall Analysis:**

REGN has historically outperformed the S&P 500, exhibiting significant growth. Currently, the stock is showing some signs of a short-term downtrend based on technical indicators and recent price movement. However, its recent earnings results were strong, suggesting a potential for future growth.

**6. Conclusion:**

While recent technical indicators and price movements suggest potential short-term downward pressure, REGN's strong historical performance and latest earnings suggest a positive long-term outlook. Further analysis of industry trends, competitor performance, and future product development plans is recommended to form a comprehensive investment decision. 
